• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
COVID-19-from emerging global threat to ongoing pandemic crisis.新冠病毒病——从新出现的全球威胁到持续的大流行危机
Proc (Bayl Univ Med Cent). 2022 May 9;35(4):468-475. doi: 10.1080/08998280.2022.2068940. eCollection 2022.
2
Pathophysiology, Transmission, Diagnosis, and Treatment of Coronavirus Disease 2019 (COVID-19): A Review.新型冠状病毒病 2019(COVID-19)的病理生理学、传播、诊断和治疗:综述。
JAMA. 2020 Aug 25;324(8):782-793. doi: 10.1001/jama.2020.12839.
3
Physical interventions to interrupt or reduce the spread of respiratory viruses.物理干预措施以阻断或减少呼吸道病毒的传播。
Cochrane Database Syst Rev. 2023 Jan 30;1(1):CD006207. doi: 10.1002/14651858.CD006207.pub6.
4
Molnupiravir, Nirmatrelvir/Ritonavir, or Sotrovimab for High-Risk COVID-19 Patients Infected by the Omicron Variant: Hospitalization, Mortality, and Time until Negative Swab Test in Real Life.莫努匹韦、奈玛特韦/利托那韦或索托维单抗用于感染奥密克戎变异株的高危COVID-19患者:现实生活中的住院率、死亡率及核酸检测转阴时间
Pharmaceuticals (Basel). 2023 May 9;16(5):721. doi: 10.3390/ph16050721.
5
Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.在流行地区,服用抗叶酸抗疟药物的人群中,叶酸补充剂与疟疾易感性和严重程度的关系。
Cochrane Database Syst Rev. 2022 Feb 1;2(2022):CD014217. doi: 10.1002/14651858.CD014217.
6
Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.COVID-19 住院成人患者使用伊马替尼的安全性和疗效:一项随机对照试验研究方案的结构化总结。
Trials. 2020 Oct 28;21(1):897. doi: 10.1186/s13063-020-04819-9.
7
SARS-CoV-2 variants and COVID-19 vaccines: Current challenges and future strategies.SARS-CoV-2 变体和 COVID-19 疫苗:当前的挑战与未来策略。
Int Rev Immunol. 2023;42(6):393-414. doi: 10.1080/08830185.2022.2079642. Epub 2022 May 28.
8
Nirmatrelvir/ritonavir and remdesivir against symptomatic treatment in high-risk COVID-19 outpatients to prevent hospitalization or death during the Omicron era: a propensity score-matched study.在奥密克戎时代,使用奈玛特韦/利托那韦和瑞德西韦对高危新冠门诊患者进行对症治疗以预防住院或死亡:一项倾向评分匹配研究
Ther Adv Infect Dis. 2024 Mar 26;11:20499361241236582. doi: 10.1177/20499361241236582. eCollection 2024 Jan-Dec.
9
Monoclonal Antibody Therapy For High-Risk Coronavirus (COVID 19) Patients With Mild To Moderate Disease Presentations (Archived)针对轻度至中度症状的高危冠状病毒(COVID-19)患者的单克隆抗体疗法(存档)
10
Infection Prevention Precautions for Routine Anesthesia Care During the SARS-CoV-2 Pandemic.SARS-CoV-2 大流行期间常规麻醉护理的感染预防措施。
Anesth Analg. 2020 Nov;131(5):1342-1354. doi: 10.1213/ANE.0000000000005169.

引用本文的文献

1
Twitter-Based Sentiment Analysis and Topic Modeling of Social Media Posts Using Natural Language Processing, to Understand People's Perspectives Regarding COVID-19 Booster Vaccine Shots in India: Crucial to Expanding Vaccination Coverage.基于推特的社交媒体帖子情感分析与主题建模:利用自然语言处理来了解印度民众对新冠疫苗加强针的看法,这对扩大疫苗接种覆盖率至关重要。
Vaccines (Basel). 2022 Nov 15;10(11):1929. doi: 10.3390/vaccines10111929.
2
Evolution, epidemiology, geographical distribution, and mutational landscape of newly emerging monkeypox virus.新出现的猴痘病毒的进化、流行病学、地理分布和突变景观。
Geroscience. 2022 Dec;44(6):2895-2911. doi: 10.1007/s11357-022-00659-4. Epub 2022 Sep 12.

本文引用的文献

1
COVID-19-Associated Hospitalizations Among Adults During SARS-CoV-2 Delta and Omicron Variant Predominance, by Race/Ethnicity and Vaccination Status - COVID-NET, 14 States, July 2021-January 2022.COVID-19 相关住院病例在 SARS-CoV-2 德尔塔和奥密克戎变异株流行期间的种族/民族差异和疫苗接种状况分析——COVID-NET,14 个州,2021 年 7 月至 2022 年 1 月。
MMWR Morb Mortal Wkly Rep. 2022 Mar 25;71(12):466-473. doi: 10.15585/mmwr.mm7112e2.
2
Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.卡司瑞韦单抗和伊德韦单抗联合治疗住院 COVID-19 患者(RECOVERY):一项随机、对照、开放标签、平台试验。
Lancet. 2022 Feb 12;399(10325):665-676. doi: 10.1016/S0140-6736(22)00163-5.
3
Durability of Anti-Spike Antibodies in Infants After Maternal COVID-19 Vaccination or Natural Infection.母亲接种 COVID-19 疫苗或自然感染后婴儿体内抗刺突抗体的持久性。
JAMA. 2022 Mar 15;327(11):1087-1089. doi: 10.1001/jama.2022.1206.
4
Viral infection and transmission in a large, well-traced outbreak caused by the SARS-CoV-2 Delta variant.新冠病毒德尔塔变异株引发的大型溯源清晰的暴发中的病毒感染和传播。
Nat Commun. 2022 Jan 24;13(1):460. doi: 10.1038/s41467-022-28089-y.
5
Early Remdesivir to Prevent Progression to Severe Covid-19 in Outpatients.瑞德西韦早期治疗可降低门诊患者重症 COVID-19 进展风险
N Engl J Med. 2022 Jan 27;386(4):305-315. doi: 10.1056/NEJMoa2116846. Epub 2021 Dec 22.
6
Molnupiravir for Oral Treatment of Covid-19 in Nonhospitalized Patients.莫努匹韦片用于非住院 COVID-19 患者的口服治疗。
N Engl J Med. 2022 Feb 10;386(6):509-520. doi: 10.1056/NEJMoa2116044. Epub 2021 Dec 16.
7
Omicron SARS-CoV-2 variant: a new chapter in the COVID-19 pandemic.奥密克戎新冠病毒变体:新冠疫情的新篇章。
Lancet. 2021 Dec 11;398(10317):2126-2128. doi: 10.1016/S0140-6736(21)02758-6. Epub 2021 Dec 3.
8
Effect of early treatment with fluvoxamine on risk of emergency care and hospitalisation among patients with COVID-19: the TOGETHER randomised, platform clinical trial.氟伏沙明早期治疗对 COVID-19 患者急诊和住院风险的影响:TOGETHER 随机、平台临床试验。
Lancet Glob Health. 2022 Jan;10(1):e42-e51. doi: 10.1016/S2214-109X(21)00448-4. Epub 2021 Oct 28.
9
BNT162b2 and ChAdOx1 nCoV-19 Vaccine Effectiveness against Death from the Delta Variant.BNT162b2和ChAdOx1 nCoV-19疫苗对德尔塔变异株所致死亡的有效性
N Engl J Med. 2021 Dec 2;385(23):2195-2197. doi: 10.1056/NEJMc2113864. Epub 2021 Oct 20.
10
Receipt of mRNA Covid-19 Vaccines and Risk of Spontaneous Abortion.接受新冠病毒mRNA疫苗与自然流产风险
N Engl J Med. 2021 Oct 14;385(16):1533-1535. doi: 10.1056/NEJMc2113891. Epub 2021 Sep 8.

新冠病毒病——从新出现的全球威胁到持续的大流行危机

COVID-19-from emerging global threat to ongoing pandemic crisis.

作者信息

Brust Karen B, Papineni Vinayika, Columbus Cristie, Arroliga Alejandro C

机构信息

Division of Infectious Disease, Department of Internal Medicine, Baylor Scott & White Medical Center - Temple, Temple, Texas.

Texas A&M Health Science Center, Texas A&M University, Austin, Texas.

出版信息

Proc (Bayl Univ Med Cent). 2022 May 9;35(4):468-475. doi: 10.1080/08998280.2022.2068940. eCollection 2022.

DOI:10.1080/08998280.2022.2068940
PMID:35754606
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9196727/
Abstract

In December 2019, China witnessed the emergence of a novel coronavirus, SARS-CoV-2. Its ability to spread quickly made it a global pandemic. The United States has been greatly affected, with more than 980,000 lives lost so far. Diagnosis is made primarily through nasopharyngeal swab for polymerase chain reaction. Point-of-care testing by antigen is less sensitive and specific and may require polymerase chain reaction confirmation. Management of the COVID-19 patient remains largely supportive. Steroids are now a therapy mainstay if the patient is hypoxic. Direct antivirals, such as nirmatrelvir/ritonavir, remdesivir, or molnupirivir, can be used if certain criteria are met. SARS-CoV-2 is transmitted primarily by inhalation of large droplets, though transmission by aerosolization may occur, particularly via certain procedures. In the hospital setting, use of personal protective equipment for the care of COVID-19 patients has largely remained the same, with full use of gowns, gloves, respirators, and eye protection. Inadequate supply at the start of the pandemic required innovative ways to reprocess and extend the use of personal protective equipment. Three vaccines are now available in the US, all with excellent efficacy against severe disease and hospitalization, though booster doses are needed to bolster waning antibody levels. The possibility of emerging variants continues to remain a threat to control of the pandemic. The leader of the World Health Organization, Dr. Tedros, has stated, "The pandemic will not be over anywhere until it's over everywhere."

摘要

2019年12月,中国出现了一种新型冠状病毒——严重急性呼吸综合征冠状病毒2(SARS-CoV-2)。其快速传播的能力使其成为全球大流行病。美国受到了极大影响,截至目前已有超过98万人丧生。诊断主要通过采集鼻咽拭子进行聚合酶链反应。抗原即时检测的敏感性和特异性较低,可能需要聚合酶链反应确认。对新冠患者的治疗在很大程度上仍以支持治疗为主。如果患者出现低氧情况,类固醇药物现在是主要治疗手段。如果符合某些标准,可以使用直接抗病毒药物,如奈玛特韦/利托那韦、瑞德西韦或莫努匹韦。SARS-CoV-2主要通过吸入大飞沫传播,不过也可能通过气溶胶传播,特别是在某些特定操作过程中。在医院环境中,对新冠患者进行护理时使用个人防护装备的情况基本保持不变,要充分使用隔离衣、手套、呼吸器和眼部防护用品。疫情初期防护用品供应不足,需要创新方法对个人防护装备进行再处理和延长其使用期限。美国现在有三种疫苗可供使用,所有这些疫苗对重症疾病和住院治疗都有很好的疗效,不过需要接种加强针来提高逐渐下降的抗体水平。新变种出现的可能性仍然是控制疫情的一大威胁。世界卫生组织总干事谭德塞博士表示:“疫情在任何地方都不会结束,除非在所有地方都结束。”